Xilio Development Inc (XLO) - Total Assets
Based on the latest financial reports, Xilio Development Inc (XLO) holds total assets worth $154.25 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xilio Development Inc - Total Assets Trend (2019–2025)
This chart illustrates how Xilio Development Inc's total assets have evolved over time, based on quarterly financial data. Also see Xilio Development Inc market cap and net worth for the company's overall valuation and market capitalisation.
Xilio Development Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Xilio Development Inc's total assets of $154.25 Million consist of 93.8% current assets and 6.2% non-current assets. Review XLO liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.9% |
| Accounts Receivable | $5.00 Million | 3.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Xilio Development Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Xilio Development Inc (XLO) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xilio Development Inc's current assets represent 93.8% of total assets in 2025, an increase from 81.5% in 2019.
- Cash Position: Cash and equivalents constituted 88.9% of total assets in 2025, up from 77.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Xilio Development Inc Competitors by Total Assets
Key competitors of Xilio Development Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Xilio Development Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.25 | 2.32 | 5.85 |
| Quick Ratio | 4.25 | 2.32 | 5.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $111.27 Million | $70.46 Million | $103.28 Million |
Xilio Development Inc - Advanced Valuation Insights
This section examines the relationship between Xilio Development Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.81 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 117.6% |
| Total Assets | $154.69 Million |
| Market Capitalization | $59.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xilio Development Inc's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Xilio Development Inc's assets grew by 117.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Xilio Development Inc (2019–2025)
The table below shows the annual total assets of Xilio Development Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $154.69 Million | +117.64% |
| 2024-12-31 | $71.08 Million | +16.66% |
| 2023-12-31 | $60.93 Million | -56.22% |
| 2022-12-31 | $139.16 Million | -37.20% |
| 2021-12-31 | $221.60 Million | +510.18% |
| 2020-12-31 | $36.32 Million | -42.10% |
| 2019-12-31 | $62.72 Million | -- |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumo… Read more